Scotland To Improve Early Patient Access to ‘Ultra-Orphan’ Drugs

Scotland is changing that way that medicines for very rare diseases are assessed by the health technology assessment body, the SMC. The changes include a new definition of “ultra-orphan medicine” and a new system for provisionally funding such products while more evidence is gathered on their effectiveness